Best Compounds for Weight Loss (2026) | Peptide Database

Join others researching Oxiracetam — share findings, ask questions, and learn from real experiences Oxiracetam (ISF-2522) is a synthetic nootropic compound belonging to the racetam family, first developed in the 1970s by ICF, an Italian pharmaceutical company. It is a hydroxylated derivative of piracetam and is approved as a prescription medication in Italy and several other European and Asian countries for the treatment of cognitive decline associated with dementia and organic brain syndromes. Among the racetams, oxiracetam is widely regarded as the most effective for logical reasoning, mathematical thinking, and technical work -- a reputation that distinguishes it from piracetam, which users more commonly associate with verbal fluency and creative thinking. Oxiracetam is well absorbed orally with high bioavailability, is not significantly metabolized by the liver, and is excreted largely unchanged by the kidneys, giving it a clean pharmacokinetic profile with minimal drug-drug interaction potential. Oxiracetam enhances cognitive function primarily through positive allosteric modulation of AMPA-type glutamate receptors, increasing the excitatory postsynaptic response to glutamate and facilitating long-term potentiation (LTP) in hippocampal and cortical circuits. This AMPA modulation is thought to underlie its effects on memory encoding and retrieval. Additionally, oxiracetam stimulates cholinergic neurotransmission by increasing the release of acetylcholine in the hippocampus and cortex, which contributes to improvements in attention, working memory, and the speed of information processing. Unlike some stimulant nootropics, oxiracetam does not act on dopaminergic or serotonergic systems, which accounts for its low abuse potential and absence of mood-altering side effects. Oxiracetam also increases phospholipid metabolism in the brain, specifically the turnover of phosphatidylcholine and phosphatidylethanolamine, which may support membrane integrity and synaptic function. The compound increases D-aspartate release in the hippocampus, providing an additional pathway for NMDA receptor activation and synaptic plasticity. Its selectivity for logical and analytical cognition, as reported by users, may relate to preferential enhancement of cortical circuits involved in sequential reasoning and working memory manipulation, though this distinction has not been rigorously dissected in controlled studies.

Join others researching Tamoxifen — share findings, ask questions, and learn from real experiences Tamoxifen is a first-generation selective estrogen receptor modulator (SERM) that has been in clinical use since the 1970s. It is FDA-approved for the treatment and prevention of estrogen receptor-positive breast cancer and remains one of the most widely prescribed cancer therapies worldwide. In the context of performance enhancement, tamoxifen is used extensively for post-cycle therapy (PCT) to restore the hypothalamic-pituitary-testicular axis after suppression from anabolic steroids, and for on-cycle gynecomastia prevention by blocking estrogen receptors in breast tissue. Tamoxifen acts as an estrogen antagonist in breast and hypothalamic tissue while functioning as a partial estrogen agonist in bone, the uterus, and the cardiovascular system. Its active metabolite endoxifen, produced via CYP2D6 metabolism, is responsible for much of its pharmacological activity. Tamoxifen competitively binds to estrogen receptors (primarily ERalpha) and exerts tissue-selective effects depending on the local coactivator and corepressor environment. In breast tissue and the hypothalamus, tamoxifen acts as an estrogen antagonist, blocking estradiol-mediated signaling. At the hypothalamus and anterior pituitary, this antagonism removes estrogen-driven negative feedback on GnRH secretion, leading to increased pulsatile GnRH release and subsequent elevation of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The rise in LH stimulates Leydig cell testosterone production, which is the basis for its use in post-cycle therapy. In bone tissue, tamoxifen acts as a partial estrogen agonist, providing a protective effect on bone mineral density. Tamoxifen is a prodrug that requires hepatic metabolism via CYP3A4 and CYP2D6 to generate its active metabolites, particularly endoxifen, which has approximately 100-fold greater affinity for the estrogen receptor than the parent compound.